deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04467840

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia

Sponsor: RedHill Biopharma Limited

Conditions COVID-19 Lung Infection
Interventions Opaganib Placebo
Updated 17 times since 2020 Last updated: Jul 21, 2025 Started: Aug 21, 2020 Primary completion: Jul 18, 2021 Completion: Jul 18, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates COVID-19 and Lung Infection and is currently completed. RedHill Biopharma Limited leads this study, which shows 17 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Nov 2023 · 26 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Aug 2025 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Sep 2024 — Aug 2025 [monthly]

    Completed PHASE2/PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  5. Nov 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

▶ Show 12 earlier versions

  1. Sep 2021 — Nov 2023 [monthly]

    Completed PHASE2_PHASE3

    Status: Recruiting → Completed

  2. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2_PHASE3

  3. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2_PHASE3

  4. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2_PHASE3

  5. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2_PHASE3

  6. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2_PHASE3

  7. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2_PHASE3

  8. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2_PHASE3

  9. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2_PHASE3

  10. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE2_PHASE3

  11. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2_PHASE3

    Status: Not Yet Recruiting → Recruiting

  12. Aug 2020 — Sep 2020 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • RedHill Biopharma Limited
Data source: RedHill Biopharma Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Antrim, United Kingdom , Ashdod, Israel , Ashkelon, Israel , Barnaul, Russia , Belo Horizonte, Brazil , Bogotá, Colombia , Bolesławiec, Poland , Cundinamarca, Colombia , Detroit, United States and 40 more locations